NCT02834013 2026-06-03Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting798 enrolled
NCT03074513 2026-03-11Atezolizumab and Bevacizumab in Treating Patients With Rare Solid TumorsM.D. Anderson Cancer CenterPhase 2 Active not recruiting133 enrolled